Home
Pipeline
Breakthrough Platforms
Partnering
About us
Investor Relations
Careers
Contact

News on home

Spexis > News on home

Latest news

Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera
Spexis announces closing of sale of preclinical antibiotics program to Basilea

This site uses cookies: Find out more.